Abbott Laboratories
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Abbott Laboratories (ABT). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Medical Devices | $11.79B 34.1% | $14.49B 33.7% · +22.9% | $14.80B 33.9% · +2.2% | $16.89B 42.1% · +14.1% | $18.99B 45.3% · +12.4% | $21.39B 48.3% · +12.6% |
| Diagnostic Products | $10.81B 31.3% | $15.53B 36.1% · +43.7% | $16.47B 37.7% · +6.1% | $9.99B 24.9% · -39.4% | $9.34B 22.3% · -6.5% | $8.94B 20.2% · -4.3% |
| Nutritional Products | $7.65B 22.1% | $8.29B 19.3% · +8.5% | $7.46B 17.1% · -10.1% | $8.15B 20.3% · +9.3% | $8.41B 20.1% · +3.2% | $8.45B 19.1% · +0.5% |
| Established Pharmaceutical Products | $4.30B 12.5% | $4.72B 11.0% · +9.6% | $4.91B 11.3% · +4.1% | $5.07B 12.6% · +3.1% | $5.19B 12.4% · +2.5% | $5.54B 12.5% · +6.6% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Medical Devices | $3.04B 25.8% | $4.53B 31.3% | $4.44B 30.0% | $5.31B 31.4% | $6.15B 32.4% | $7.21B 33.7% |
| Diagnostic Products | $3.73B 34.5% | $6.24B 40.2% | $6.64B 40.3% | $2.43B 24.4% | $2.07B 22.2% | $1.74B 19.5% |
| Nutritional Products | $1.75B 22.9% | $1.76B 21.3% | $706.0M 9.5% | $1.33B 16.3% | $1.51B 17.9% | $1.56B 18.4% |
| Established Pharmaceutical Products | $794.0M 18.5% | $889.0M 18.8% | $1.05B 21.4% | $1.21B 23.8% | $1.23B 23.7% | $1.29B 23.3% |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.